nodes	percent_of_prediction	percent_of_DWPC	metapath
Celecoxib—Etoricoxib—Vemurafenib—skin cancer	0.297	0.591	CrCrCtD
Celecoxib—Etoricoxib—Vismodegib—skin cancer	0.206	0.409	CrCrCtD
Celecoxib—PTGS2—skin cancer	0.118	1	CbGaD
Celecoxib—ORM1—Vismodegib—skin cancer	0.057	0.237	CbGbCtD
Celecoxib—ORM1—Vemurafenib—skin cancer	0.0451	0.187	CbGbCtD
Celecoxib—ALB—Vismodegib—skin cancer	0.024	0.0997	CbGbCtD
Celecoxib—ABCC4—Fluorouracil—skin cancer	0.023	0.0956	CbGbCtD
Celecoxib—ALB—Vemurafenib—skin cancer	0.019	0.0788	CbGbCtD
Celecoxib—CYP2C9—Vismodegib—skin cancer	0.0129	0.0538	CbGbCtD
Celecoxib—CYP3A4—Imiquimod—skin cancer	0.0109	0.0451	CbGbCtD
Celecoxib—CYP3A4—Temozolomide—skin cancer	0.0109	0.0451	CbGbCtD
Celecoxib—CYP2D6—Vemurafenib—skin cancer	0.00935	0.0389	CbGbCtD
Celecoxib—ALB—Fluorouracil—skin cancer	0.00853	0.0354	CbGbCtD
Celecoxib—CYP3A4—Vismodegib—skin cancer	0.00752	0.0313	CbGbCtD
Celecoxib—CYP3A4—Vemurafenib—skin cancer	0.00595	0.0247	CbGbCtD
Celecoxib—CYP2C9—Fluorouracil—skin cancer	0.0046	0.0191	CbGbCtD
Celecoxib—CA6—ear—skin cancer	0.00251	0.0932	CbGeAlD
Celecoxib—CYP3A4—Docetaxel—skin cancer	0.00204	0.00848	CbGbCtD
Celecoxib—PDPK1—nipple—skin cancer	0.00148	0.055	CbGeAlD
Celecoxib—CA6—hair follicle—skin cancer	0.00132	0.0491	CbGeAlD
Celecoxib—MAPK14—hair follicle—skin cancer	0.00117	0.0434	CbGeAlD
Celecoxib—MAPK14—blood vessel—skin cancer	0.0011	0.0407	CbGeAlD
Celecoxib—MAPK14—neck—skin cancer	0.000786	0.0291	CbGeAlD
Celecoxib—PDPK1—lymphoid tissue—skin cancer	0.00077	0.0285	CbGeAlD
Celecoxib—PDPK1—female reproductive system—skin cancer	0.000743	0.0275	CbGeAlD
Celecoxib—PTGS2—leg—skin cancer	0.000741	0.0275	CbGeAlD
Celecoxib—CA5A—female reproductive system—skin cancer	0.000697	0.0258	CbGeAlD
Celecoxib—PTGS2—hindlimb—skin cancer	0.000661	0.0245	CbGeAlD
Celecoxib—CA4—nerve—skin cancer	0.000657	0.0244	CbGeAlD
Celecoxib—PDPK1—head—skin cancer	0.00062	0.023	CbGeAlD
Celecoxib—PTGS2—appendage—skin cancer	0.000567	0.021	CbGeAlD
Celecoxib—MAPK14—connective tissue—skin cancer	0.000563	0.0209	CbGeAlD
Celecoxib—MAPK14—epithelium—skin cancer	0.000535	0.0198	CbGeAlD
Celecoxib—MAPK14—skin of body—skin cancer	0.000508	0.0188	CbGeAlD
Celecoxib—Etoricoxib—PTGS2—skin cancer	0.000497	1	CrCbGaD
Celecoxib—PTGS2—skin epidermis—skin cancer	0.000472	0.0175	CbGeAlD
Celecoxib—CA2—hair follicle—skin cancer	0.000456	0.0169	CbGeAlD
Celecoxib—PDPK1—lymph node—skin cancer	0.000434	0.0161	CbGeAlD
Celecoxib—CA12—connective tissue—skin cancer	0.000427	0.0158	CbGeAlD
Celecoxib—MAPK14—lymphoid tissue—skin cancer	0.000412	0.0153	CbGeAlD
Celecoxib—CA9—female reproductive system—skin cancer	0.000407	0.0151	CbGeAlD
Celecoxib—MAPK14—female reproductive system—skin cancer	0.000397	0.0147	CbGeAlD
Celecoxib—CA6—head—skin cancer	0.000375	0.0139	CbGeAlD
Celecoxib—CA4—nipple—skin cancer	0.000373	0.0138	CbGeAlD
Celecoxib—CA4—neck—skin cancer	0.000369	0.0137	CbGeAlD
Celecoxib—PTGS2—endothelium—skin cancer	0.000342	0.0127	CbGeAlD
Celecoxib—MAPK14—head—skin cancer	0.000332	0.0123	CbGeAlD
Celecoxib—PTGS2—blood vessel—skin cancer	0.000316	0.0117	CbGeAlD
Celecoxib—CA5B—mammalian vulva—skin cancer	0.000316	0.0117	CbGeAlD
Celecoxib—CA2—nipple—skin cancer	0.000309	0.0115	CbGeAlD
Celecoxib—CA2—neck—skin cancer	0.000306	0.0113	CbGeAlD
Celecoxib—CA12—female reproductive system—skin cancer	0.000301	0.0112	CbGeAlD
Celecoxib—CA5B—female reproductive system—skin cancer	0.00027	0.01	CbGeAlD
Celecoxib—CA12—head—skin cancer	0.000252	0.00933	CbGeAlD
Celecoxib—ORM1—female reproductive system—skin cancer	0.000239	0.00886	CbGeAlD
Celecoxib—MAPK14—lymph node—skin cancer	0.000232	0.00861	CbGeAlD
Celecoxib—CA5B—head—skin cancer	0.000226	0.00837	CbGeAlD
Celecoxib—CA2—connective tissue—skin cancer	0.000219	0.00813	CbGeAlD
Celecoxib—CA2—epithelium—skin cancer	0.000208	0.00772	CbGeAlD
Celecoxib—ABCC4—female reproductive system—skin cancer	0.000203	0.00752	CbGeAlD
Celecoxib—CA2—skin of body—skin cancer	0.000198	0.00734	CbGeAlD
Celecoxib—CA4—female reproductive system—skin cancer	0.000187	0.00692	CbGeAlD
Celecoxib—CA2—mammalian vulva—skin cancer	0.000181	0.0067	CbGeAlD
Celecoxib—ABCC4—head—skin cancer	0.00017	0.00628	CbGeAlD
Celecoxib—PTGS2—connective tissue—skin cancer	0.000162	0.006	CbGeAlD
Celecoxib—CA2—lymphoid tissue—skin cancer	0.00016	0.00595	CbGeAlD
Celecoxib—CA5B—lymph node—skin cancer	0.000158	0.00586	CbGeAlD
Celecoxib—CA4—head—skin cancer	0.000156	0.00578	CbGeAlD
Celecoxib—CA2—female reproductive system—skin cancer	0.000155	0.00573	CbGeAlD
Celecoxib—PTGS2—epithelium—skin cancer	0.000154	0.0057	CbGeAlD
Celecoxib—PTGS2—skin of body—skin cancer	0.000146	0.00542	CbGeAlD
Celecoxib—ORM1—lymph node—skin cancer	0.00014	0.00518	CbGeAlD
Celecoxib—CYP2C9—female reproductive system—skin cancer	0.000131	0.00485	CbGeAlD
Celecoxib—CA2—head—skin cancer	0.000129	0.00479	CbGeAlD
Celecoxib—ALB—lymph node—skin cancer	0.000123	0.00455	CbGeAlD
Celecoxib—ABCC4—lymph node—skin cancer	0.000119	0.0044	CbGeAlD
Celecoxib—PTGS2—lymphoid tissue—skin cancer	0.000118	0.00439	CbGeAlD
Celecoxib—PTGS2—female reproductive system—skin cancer	0.000114	0.00423	CbGeAlD
Celecoxib—CA4—lymph node—skin cancer	0.000109	0.00405	CbGeAlD
Celecoxib—CYP3A4—female reproductive system—skin cancer	9.98e-05	0.0037	CbGeAlD
Celecoxib—CYP2D6—female reproductive system—skin cancer	9.82e-05	0.00364	CbGeAlD
Celecoxib—PTGS2—head—skin cancer	9.54e-05	0.00354	CbGeAlD
Celecoxib—CA2—lymph node—skin cancer	9.05e-05	0.00335	CbGeAlD
Celecoxib—CYP2D6—head—skin cancer	8.2e-05	0.00304	CbGeAlD
Celecoxib—Haemoglobin—Fluorouracil—skin cancer	7.52e-05	0.000974	CcSEcCtD
Celecoxib—Leukopenia—Bleomycin—skin cancer	7.51e-05	0.000971	CcSEcCtD
Celecoxib—Rhinitis—Fluorouracil—skin cancer	7.51e-05	0.000971	CcSEcCtD
Celecoxib—Haemorrhage—Fluorouracil—skin cancer	7.49e-05	0.000969	CcSEcCtD
Celecoxib—Dizziness—Vemurafenib—skin cancer	7.47e-05	0.000967	CcSEcCtD
Celecoxib—Hypoaesthesia—Fluorouracil—skin cancer	7.45e-05	0.000964	CcSEcCtD
Celecoxib—Pharyngitis—Fluorouracil—skin cancer	7.43e-05	0.000962	CcSEcCtD
Celecoxib—Angiopathy—Temozolomide—skin cancer	7.37e-05	0.000954	CcSEcCtD
Celecoxib—Ataxia—Docetaxel—skin cancer	7.34e-05	0.00095	CcSEcCtD
Celecoxib—Immune system disorder—Temozolomide—skin cancer	7.34e-05	0.00095	CcSEcCtD
Celecoxib—Mediastinal disorder—Temozolomide—skin cancer	7.32e-05	0.000948	CcSEcCtD
Celecoxib—Cough—Bleomycin—skin cancer	7.32e-05	0.000947	CcSEcCtD
Celecoxib—Anaemia—Dactinomycin—skin cancer	7.23e-05	0.000935	CcSEcCtD
Celecoxib—Liver function test abnormal—Docetaxel—skin cancer	7.21e-05	0.000933	CcSEcCtD
Celecoxib—Vomiting—Vemurafenib—skin cancer	7.18e-05	0.000929	CcSEcCtD
Celecoxib—Alopecia—Temozolomide—skin cancer	7.18e-05	0.000929	CcSEcCtD
Celecoxib—Dry skin—Docetaxel—skin cancer	7.16e-05	0.000927	CcSEcCtD
Celecoxib—Myalgia—Bleomycin—skin cancer	7.14e-05	0.000924	CcSEcCtD
Celecoxib—Chest pain—Bleomycin—skin cancer	7.14e-05	0.000924	CcSEcCtD
Celecoxib—Abdominal pain upper—Docetaxel—skin cancer	7.13e-05	0.000923	CcSEcCtD
Celecoxib—Rash—Vemurafenib—skin cancer	7.12e-05	0.000922	CcSEcCtD
Celecoxib—Mental disorder—Temozolomide—skin cancer	7.12e-05	0.000921	CcSEcCtD
Celecoxib—Dermatitis—Vemurafenib—skin cancer	7.12e-05	0.000921	CcSEcCtD
Celecoxib—Hypersensitivity—Imiquimod—skin cancer	7.1e-05	0.000918	CcSEcCtD
Celecoxib—Headache—Vemurafenib—skin cancer	7.08e-05	0.000916	CcSEcCtD
Celecoxib—Breast disorder—Docetaxel—skin cancer	7.06e-05	0.000913	CcSEcCtD
Celecoxib—Aspartate aminotransferase increased—Docetaxel—skin cancer	7.03e-05	0.00091	CcSEcCtD
Celecoxib—Toxic epidermal necrolysis—Docetaxel—skin cancer	7.03e-05	0.00091	CcSEcCtD
Celecoxib—Leukopenia—Dactinomycin—skin cancer	7e-05	0.000906	CcSEcCtD
Celecoxib—Nasopharyngitis—Docetaxel—skin cancer	6.98e-05	0.000904	CcSEcCtD
Celecoxib—Dysgeusia—Temozolomide—skin cancer	6.93e-05	0.000896	CcSEcCtD
Celecoxib—Asthenia—Imiquimod—skin cancer	6.91e-05	0.000894	CcSEcCtD
Celecoxib—Confusional state—Bleomycin—skin cancer	6.9e-05	0.000893	CcSEcCtD
Celecoxib—Alanine aminotransferase increased—Docetaxel—skin cancer	6.89e-05	0.000891	CcSEcCtD
Celecoxib—Anaphylactic shock—Bleomycin—skin cancer	6.84e-05	0.000886	CcSEcCtD
Celecoxib—Oedema—Bleomycin—skin cancer	6.84e-05	0.000886	CcSEcCtD
Celecoxib—Back pain—Temozolomide—skin cancer	6.84e-05	0.000885	CcSEcCtD
Celecoxib—Pruritus—Imiquimod—skin cancer	6.82e-05	0.000882	CcSEcCtD
Celecoxib—Infection—Bleomycin—skin cancer	6.8e-05	0.00088	CcSEcCtD
Celecoxib—Dysphagia—Docetaxel—skin cancer	6.75e-05	0.000874	CcSEcCtD
Celecoxib—Nausea—Vemurafenib—skin cancer	6.71e-05	0.000868	CcSEcCtD
Celecoxib—Thrombocytopenia—Bleomycin—skin cancer	6.7e-05	0.000867	CcSEcCtD
Celecoxib—Arrhythmia—Fluorouracil—skin cancer	6.69e-05	0.000865	CcSEcCtD
Celecoxib—PTGS2—lymph node—skin cancer	6.68e-05	0.00248	CbGeAlD
Celecoxib—Vision blurred—Temozolomide—skin cancer	6.67e-05	0.000863	CcSEcCtD
Celecoxib—Myalgia—Dactinomycin—skin cancer	6.66e-05	0.000862	CcSEcCtD
Celecoxib—Bronchospasm—Docetaxel—skin cancer	6.64e-05	0.000859	CcSEcCtD
Celecoxib—Alopecia—Fluorouracil—skin cancer	6.62e-05	0.000856	CcSEcCtD
Celecoxib—Diarrhoea—Imiquimod—skin cancer	6.59e-05	0.000853	CcSEcCtD
Celecoxib—Angina pectoris—Docetaxel—skin cancer	6.58e-05	0.000851	CcSEcCtD
Celecoxib—Anaemia—Temozolomide—skin cancer	6.54e-05	0.000846	CcSEcCtD
Celecoxib—Anorexia—Bleomycin—skin cancer	6.52e-05	0.000844	CcSEcCtD
Celecoxib—Angioedema—Temozolomide—skin cancer	6.46e-05	0.000836	CcSEcCtD
Celecoxib—Pancytopenia—Docetaxel—skin cancer	6.41e-05	0.00083	CcSEcCtD
Celecoxib—Oedema—Dactinomycin—skin cancer	6.38e-05	0.000826	CcSEcCtD
Celecoxib—Dizziness—Imiquimod—skin cancer	6.37e-05	0.000824	CcSEcCtD
Celecoxib—Vertigo—Temozolomide—skin cancer	6.36e-05	0.000822	CcSEcCtD
Celecoxib—Infection—Dactinomycin—skin cancer	6.34e-05	0.000821	CcSEcCtD
Celecoxib—Leukopenia—Temozolomide—skin cancer	6.33e-05	0.000819	CcSEcCtD
Celecoxib—Palpitations—Temozolomide—skin cancer	6.25e-05	0.000809	CcSEcCtD
Celecoxib—Thrombocytopenia—Dactinomycin—skin cancer	6.25e-05	0.000809	CcSEcCtD
Celecoxib—Musculoskeletal discomfort—Bleomycin—skin cancer	6.24e-05	0.000807	CcSEcCtD
Celecoxib—Cough—Temozolomide—skin cancer	6.17e-05	0.000799	CcSEcCtD
Celecoxib—Paraesthesia—Bleomycin—skin cancer	6.15e-05	0.000795	CcSEcCtD
Celecoxib—Weight increased—Docetaxel—skin cancer	6.14e-05	0.000795	CcSEcCtD
Celecoxib—Vision blurred—Fluorouracil—skin cancer	6.14e-05	0.000795	CcSEcCtD
Celecoxib—Vomiting—Imiquimod—skin cancer	6.12e-05	0.000793	CcSEcCtD
Celecoxib—Hypertension—Temozolomide—skin cancer	6.11e-05	0.00079	CcSEcCtD
Celecoxib—Dyspnoea—Bleomycin—skin cancer	6.1e-05	0.00079	CcSEcCtD
Celecoxib—Anorexia—Dactinomycin—skin cancer	6.08e-05	0.000787	CcSEcCtD
Celecoxib—Rash—Imiquimod—skin cancer	6.07e-05	0.000786	CcSEcCtD
Celecoxib—Dermatitis—Imiquimod—skin cancer	6.07e-05	0.000785	CcSEcCtD
Celecoxib—Pneumonia—Docetaxel—skin cancer	6.05e-05	0.000783	CcSEcCtD
Celecoxib—Headache—Imiquimod—skin cancer	6.03e-05	0.000781	CcSEcCtD
Celecoxib—Anaemia—Fluorouracil—skin cancer	6.02e-05	0.00078	CcSEcCtD
Celecoxib—Myalgia—Temozolomide—skin cancer	6.02e-05	0.000779	CcSEcCtD
Celecoxib—Arthralgia—Temozolomide—skin cancer	6.02e-05	0.000779	CcSEcCtD
Celecoxib—Infestation NOS—Docetaxel—skin cancer	6.02e-05	0.000779	CcSEcCtD
Celecoxib—Infestation—Docetaxel—skin cancer	6.02e-05	0.000779	CcSEcCtD
Celecoxib—Anxiety—Temozolomide—skin cancer	6e-05	0.000777	CcSEcCtD
Celecoxib—Unspecified disorder of skin and subcutaneous tissue—Temozolomide—skin cancer	5.98e-05	0.000774	CcSEcCtD
Celecoxib—Stevens-Johnson syndrome—Docetaxel—skin cancer	5.97e-05	0.000772	CcSEcCtD
Celecoxib—Decreased appetite—Bleomycin—skin cancer	5.95e-05	0.00077	CcSEcCtD
Celecoxib—Acute coronary syndrome—Docetaxel—skin cancer	5.93e-05	0.000768	CcSEcCtD
Celecoxib—Myocardial infarction—Docetaxel—skin cancer	5.9e-05	0.000764	CcSEcCtD
Celecoxib—Neuropathy peripheral—Docetaxel—skin cancer	5.9e-05	0.000764	CcSEcCtD
Celecoxib—Dry mouth—Temozolomide—skin cancer	5.89e-05	0.000762	CcSEcCtD
Celecoxib—Stomatitis—Docetaxel—skin cancer	5.87e-05	0.000759	CcSEcCtD
Celecoxib—Jaundice—Docetaxel—skin cancer	5.87e-05	0.000759	CcSEcCtD
Celecoxib—Conjunctivitis—Docetaxel—skin cancer	5.85e-05	0.000757	CcSEcCtD
Celecoxib—Leukopenia—Fluorouracil—skin cancer	5.83e-05	0.000755	CcSEcCtD
Celecoxib—Confusional state—Temozolomide—skin cancer	5.82e-05	0.000753	CcSEcCtD
Celecoxib—Musculoskeletal discomfort—Dactinomycin—skin cancer	5.82e-05	0.000753	CcSEcCtD
Celecoxib—Anaphylactic shock—Temozolomide—skin cancer	5.77e-05	0.000747	CcSEcCtD
Celecoxib—Oedema—Temozolomide—skin cancer	5.77e-05	0.000747	CcSEcCtD
Celecoxib—Infection—Temozolomide—skin cancer	5.74e-05	0.000742	CcSEcCtD
Celecoxib—Nausea—Imiquimod—skin cancer	5.72e-05	0.00074	CcSEcCtD
Celecoxib—Hepatobiliary disease—Docetaxel—skin cancer	5.69e-05	0.000737	CcSEcCtD
Celecoxib—Epistaxis—Docetaxel—skin cancer	5.68e-05	0.000735	CcSEcCtD
Celecoxib—Nervous system disorder—Temozolomide—skin cancer	5.66e-05	0.000733	CcSEcCtD
Celecoxib—Thrombocytopenia—Temozolomide—skin cancer	5.65e-05	0.000731	CcSEcCtD
Celecoxib—Feeling abnormal—Bleomycin—skin cancer	5.64e-05	0.00073	CcSEcCtD
Celecoxib—Agranulocytosis—Docetaxel—skin cancer	5.62e-05	0.000727	CcSEcCtD
Celecoxib—Skin disorder—Temozolomide—skin cancer	5.61e-05	0.000726	CcSEcCtD
Celecoxib—Hyperhidrosis—Temozolomide—skin cancer	5.58e-05	0.000722	CcSEcCtD
Celecoxib—Chest pain—Fluorouracil—skin cancer	5.55e-05	0.000718	CcSEcCtD
Celecoxib—Myalgia—Fluorouracil—skin cancer	5.55e-05	0.000718	CcSEcCtD
Celecoxib—Decreased appetite—Dactinomycin—skin cancer	5.55e-05	0.000718	CcSEcCtD
Celecoxib—Fatigue—Dactinomycin—skin cancer	5.5e-05	0.000712	CcSEcCtD
Celecoxib—Anorexia—Temozolomide—skin cancer	5.5e-05	0.000712	CcSEcCtD
Celecoxib—Urticaria—Bleomycin—skin cancer	5.44e-05	0.000704	CcSEcCtD
Celecoxib—Haemoglobin—Docetaxel—skin cancer	5.43e-05	0.000703	CcSEcCtD
Celecoxib—Rhinitis—Docetaxel—skin cancer	5.42e-05	0.000701	CcSEcCtD
Celecoxib—Body temperature increased—Bleomycin—skin cancer	5.41e-05	0.0007	CcSEcCtD
Celecoxib—Haemorrhage—Docetaxel—skin cancer	5.4e-05	0.000699	CcSEcCtD
Celecoxib—Hepatitis—Docetaxel—skin cancer	5.4e-05	0.000699	CcSEcCtD
Celecoxib—Hypoaesthesia—Docetaxel—skin cancer	5.38e-05	0.000696	CcSEcCtD
Celecoxib—Confusional state—Fluorouracil—skin cancer	5.36e-05	0.000694	CcSEcCtD
Celecoxib—Pharyngitis—Docetaxel—skin cancer	5.36e-05	0.000694	CcSEcCtD
Celecoxib—Urinary tract disorder—Docetaxel—skin cancer	5.34e-05	0.000691	CcSEcCtD
Celecoxib—Oedema peripheral—Docetaxel—skin cancer	5.32e-05	0.000689	CcSEcCtD
Celecoxib—Oedema—Fluorouracil—skin cancer	5.32e-05	0.000688	CcSEcCtD
Celecoxib—Anaphylactic shock—Fluorouracil—skin cancer	5.32e-05	0.000688	CcSEcCtD
Celecoxib—Connective tissue disorder—Docetaxel—skin cancer	5.31e-05	0.000687	CcSEcCtD
Celecoxib—Urethral disorder—Docetaxel—skin cancer	5.3e-05	0.000685	CcSEcCtD
Celecoxib—Infection—Fluorouracil—skin cancer	5.28e-05	0.000684	CcSEcCtD
Celecoxib—Feeling abnormal—Dactinomycin—skin cancer	5.26e-05	0.000681	CcSEcCtD
Celecoxib—Musculoskeletal discomfort—Temozolomide—skin cancer	5.26e-05	0.000681	CcSEcCtD
Celecoxib—Insomnia—Temozolomide—skin cancer	5.22e-05	0.000676	CcSEcCtD
Celecoxib—Gastrointestinal pain—Dactinomycin—skin cancer	5.22e-05	0.000675	CcSEcCtD
Celecoxib—Nervous system disorder—Fluorouracil—skin cancer	5.22e-05	0.000675	CcSEcCtD
Celecoxib—Thrombocytopenia—Fluorouracil—skin cancer	5.21e-05	0.000674	CcSEcCtD
Celecoxib—Tachycardia—Fluorouracil—skin cancer	5.19e-05	0.000672	CcSEcCtD
Celecoxib—Paraesthesia—Temozolomide—skin cancer	5.18e-05	0.000671	CcSEcCtD
Celecoxib—Dyspnoea—Temozolomide—skin cancer	5.15e-05	0.000666	CcSEcCtD
Celecoxib—Somnolence—Temozolomide—skin cancer	5.13e-05	0.000664	CcSEcCtD
Celecoxib—Erythema multiforme—Docetaxel—skin cancer	5.11e-05	0.000661	CcSEcCtD
Celecoxib—Dyspepsia—Temozolomide—skin cancer	5.08e-05	0.000658	CcSEcCtD
Celecoxib—Anorexia—Fluorouracil—skin cancer	5.07e-05	0.000656	CcSEcCtD
Celecoxib—Eye disorder—Docetaxel—skin cancer	5.05e-05	0.000653	CcSEcCtD
Celecoxib—Body temperature increased—Dactinomycin—skin cancer	5.05e-05	0.000653	CcSEcCtD
Celecoxib—Abdominal pain—Dactinomycin—skin cancer	5.05e-05	0.000653	CcSEcCtD
Celecoxib—Hypersensitivity—Bleomycin—skin cancer	5.04e-05	0.000652	CcSEcCtD
Celecoxib—Decreased appetite—Temozolomide—skin cancer	5.02e-05	0.000649	CcSEcCtD
Celecoxib—Cardiac disorder—Docetaxel—skin cancer	5.02e-05	0.000649	CcSEcCtD
Celecoxib—Flushing—Docetaxel—skin cancer	5.02e-05	0.000649	CcSEcCtD
Celecoxib—Gastrointestinal disorder—Temozolomide—skin cancer	4.98e-05	0.000645	CcSEcCtD
Celecoxib—Fatigue—Temozolomide—skin cancer	4.98e-05	0.000644	CcSEcCtD
Celecoxib—Constipation—Temozolomide—skin cancer	4.94e-05	0.000639	CcSEcCtD
Celecoxib—Asthenia—Bleomycin—skin cancer	4.91e-05	0.000635	CcSEcCtD
Celecoxib—Angiopathy—Docetaxel—skin cancer	4.9e-05	0.000634	CcSEcCtD
Celecoxib—Immune system disorder—Docetaxel—skin cancer	4.88e-05	0.000632	CcSEcCtD
Celecoxib—Mediastinal disorder—Docetaxel—skin cancer	4.87e-05	0.00063	CcSEcCtD
Celecoxib—Musculoskeletal discomfort—Fluorouracil—skin cancer	4.85e-05	0.000627	CcSEcCtD
Celecoxib—Pruritus—Bleomycin—skin cancer	4.84e-05	0.000627	CcSEcCtD
Celecoxib—Arrhythmia—Docetaxel—skin cancer	4.83e-05	0.000625	CcSEcCtD
Celecoxib—Insomnia—Fluorouracil—skin cancer	4.81e-05	0.000623	CcSEcCtD
Celecoxib—Paraesthesia—Fluorouracil—skin cancer	4.78e-05	0.000618	CcSEcCtD
Celecoxib—Alopecia—Docetaxel—skin cancer	4.78e-05	0.000618	CcSEcCtD
Celecoxib—Feeling abnormal—Temozolomide—skin cancer	4.76e-05	0.000616	CcSEcCtD
Celecoxib—Dyspnoea—Fluorouracil—skin cancer	4.74e-05	0.000614	CcSEcCtD
Celecoxib—Mental disorder—Docetaxel—skin cancer	4.73e-05	0.000613	CcSEcCtD
Celecoxib—Somnolence—Fluorouracil—skin cancer	4.73e-05	0.000612	CcSEcCtD
Celecoxib—Gastrointestinal pain—Temozolomide—skin cancer	4.72e-05	0.000611	CcSEcCtD
Celecoxib—Hypersensitivity—Dactinomycin—skin cancer	4.7e-05	0.000609	CcSEcCtD
Celecoxib—Dyspepsia—Fluorouracil—skin cancer	4.68e-05	0.000606	CcSEcCtD
Celecoxib—Decreased appetite—Fluorouracil—skin cancer	4.62e-05	0.000598	CcSEcCtD
Celecoxib—Dysgeusia—Docetaxel—skin cancer	4.61e-05	0.000596	CcSEcCtD
Celecoxib—Gastrointestinal disorder—Fluorouracil—skin cancer	4.59e-05	0.000594	CcSEcCtD
Celecoxib—Urticaria—Temozolomide—skin cancer	4.59e-05	0.000593	CcSEcCtD
Celecoxib—Asthenia—Dactinomycin—skin cancer	4.58e-05	0.000593	CcSEcCtD
Celecoxib—Abdominal pain—Temozolomide—skin cancer	4.56e-05	0.000591	CcSEcCtD
Celecoxib—Body temperature increased—Temozolomide—skin cancer	4.56e-05	0.000591	CcSEcCtD
Celecoxib—Back pain—Docetaxel—skin cancer	4.55e-05	0.000589	CcSEcCtD
Celecoxib—Muscle spasms—Docetaxel—skin cancer	4.52e-05	0.000585	CcSEcCtD
Celecoxib—Feeling abnormal—Fluorouracil—skin cancer	4.38e-05	0.000567	CcSEcCtD
Celecoxib—Diarrhoea—Dactinomycin—skin cancer	4.37e-05	0.000565	CcSEcCtD
Celecoxib—Vomiting—Bleomycin—skin cancer	4.35e-05	0.000563	CcSEcCtD
Celecoxib—Anaemia—Docetaxel—skin cancer	4.35e-05	0.000563	CcSEcCtD
Celecoxib—Rash—Bleomycin—skin cancer	4.32e-05	0.000558	CcSEcCtD
Celecoxib—Dermatitis—Bleomycin—skin cancer	4.31e-05	0.000558	CcSEcCtD
Celecoxib—Hypersensitivity—Temozolomide—skin cancer	4.25e-05	0.00055	CcSEcCtD
Celecoxib—Urticaria—Fluorouracil—skin cancer	4.23e-05	0.000547	CcSEcCtD
Celecoxib—Syncope—Docetaxel—skin cancer	4.22e-05	0.000546	CcSEcCtD
Celecoxib—Leukopenia—Docetaxel—skin cancer	4.21e-05	0.000545	CcSEcCtD
Celecoxib—Body temperature increased—Fluorouracil—skin cancer	4.2e-05	0.000544	CcSEcCtD
Celecoxib—Palpitations—Docetaxel—skin cancer	4.16e-05	0.000538	CcSEcCtD
Celecoxib—Asthenia—Temozolomide—skin cancer	4.14e-05	0.000536	CcSEcCtD
Celecoxib—Loss of consciousness—Docetaxel—skin cancer	4.13e-05	0.000535	CcSEcCtD
Celecoxib—Cough—Docetaxel—skin cancer	4.1e-05	0.000531	CcSEcCtD
Celecoxib—Pruritus—Temozolomide—skin cancer	4.08e-05	0.000529	CcSEcCtD
Celecoxib—Nausea—Bleomycin—skin cancer	4.07e-05	0.000526	CcSEcCtD
Celecoxib—Hypertension—Docetaxel—skin cancer	4.06e-05	0.000526	CcSEcCtD
Celecoxib—Vomiting—Dactinomycin—skin cancer	4.06e-05	0.000525	CcSEcCtD
Celecoxib—Rash—Dactinomycin—skin cancer	4.02e-05	0.000521	CcSEcCtD
Celecoxib—Chest pain—Docetaxel—skin cancer	4e-05	0.000518	CcSEcCtD
Celecoxib—Arthralgia—Docetaxel—skin cancer	4e-05	0.000518	CcSEcCtD
Celecoxib—Myalgia—Docetaxel—skin cancer	4e-05	0.000518	CcSEcCtD
Celecoxib—Unspecified disorder of skin and subcutaneous tissue—Docetaxel—skin cancer	3.98e-05	0.000515	CcSEcCtD
Celecoxib—Diarrhoea—Temozolomide—skin cancer	3.95e-05	0.000511	CcSEcCtD
Celecoxib—Hypersensitivity—Fluorouracil—skin cancer	3.92e-05	0.000507	CcSEcCtD
Celecoxib—Dry mouth—Docetaxel—skin cancer	3.92e-05	0.000507	CcSEcCtD
Celecoxib—Confusional state—Docetaxel—skin cancer	3.87e-05	0.000501	CcSEcCtD
Celecoxib—Oedema—Docetaxel—skin cancer	3.84e-05	0.000497	CcSEcCtD
Celecoxib—Anaphylactic shock—Docetaxel—skin cancer	3.84e-05	0.000497	CcSEcCtD
Celecoxib—Dizziness—Temozolomide—skin cancer	3.82e-05	0.000494	CcSEcCtD
Celecoxib—Infection—Docetaxel—skin cancer	3.81e-05	0.000494	CcSEcCtD
Celecoxib—Nausea—Dactinomycin—skin cancer	3.79e-05	0.000491	CcSEcCtD
Celecoxib—Shock—Docetaxel—skin cancer	3.78e-05	0.000489	CcSEcCtD
Celecoxib—Nervous system disorder—Docetaxel—skin cancer	3.76e-05	0.000487	CcSEcCtD
Celecoxib—Pruritus—Fluorouracil—skin cancer	3.76e-05	0.000487	CcSEcCtD
Celecoxib—Thrombocytopenia—Docetaxel—skin cancer	3.76e-05	0.000486	CcSEcCtD
Celecoxib—Tachycardia—Docetaxel—skin cancer	3.75e-05	0.000485	CcSEcCtD
Celecoxib—Skin disorder—Docetaxel—skin cancer	3.73e-05	0.000483	CcSEcCtD
Celecoxib—Vomiting—Temozolomide—skin cancer	3.67e-05	0.000475	CcSEcCtD
Celecoxib—Anorexia—Docetaxel—skin cancer	3.66e-05	0.000474	CcSEcCtD
Celecoxib—Rash—Temozolomide—skin cancer	3.64e-05	0.000471	CcSEcCtD
Celecoxib—Diarrhoea—Fluorouracil—skin cancer	3.64e-05	0.000471	CcSEcCtD
Celecoxib—Dermatitis—Temozolomide—skin cancer	3.64e-05	0.000471	CcSEcCtD
Celecoxib—Headache—Temozolomide—skin cancer	3.62e-05	0.000468	CcSEcCtD
Celecoxib—Dizziness—Fluorouracil—skin cancer	3.52e-05	0.000455	CcSEcCtD
Celecoxib—Musculoskeletal discomfort—Docetaxel—skin cancer	3.5e-05	0.000453	CcSEcCtD
Celecoxib—Insomnia—Docetaxel—skin cancer	3.47e-05	0.000449	CcSEcCtD
Celecoxib—Paraesthesia—Docetaxel—skin cancer	3.45e-05	0.000446	CcSEcCtD
Celecoxib—Nausea—Temozolomide—skin cancer	3.43e-05	0.000444	CcSEcCtD
Celecoxib—Dyspnoea—Docetaxel—skin cancer	3.42e-05	0.000443	CcSEcCtD
Celecoxib—Somnolence—Docetaxel—skin cancer	3.41e-05	0.000442	CcSEcCtD
Celecoxib—Vomiting—Fluorouracil—skin cancer	3.38e-05	0.000438	CcSEcCtD
Celecoxib—Dyspepsia—Docetaxel—skin cancer	3.38e-05	0.000437	CcSEcCtD
Celecoxib—Rash—Fluorouracil—skin cancer	3.35e-05	0.000434	CcSEcCtD
Celecoxib—Dermatitis—Fluorouracil—skin cancer	3.35e-05	0.000434	CcSEcCtD
Celecoxib—Decreased appetite—Docetaxel—skin cancer	3.34e-05	0.000432	CcSEcCtD
Celecoxib—Headache—Fluorouracil—skin cancer	3.33e-05	0.000431	CcSEcCtD
Celecoxib—Gastrointestinal disorder—Docetaxel—skin cancer	3.31e-05	0.000429	CcSEcCtD
Celecoxib—Fatigue—Docetaxel—skin cancer	3.31e-05	0.000428	CcSEcCtD
Celecoxib—Constipation—Docetaxel—skin cancer	3.28e-05	0.000425	CcSEcCtD
Celecoxib—Feeling abnormal—Docetaxel—skin cancer	3.16e-05	0.000409	CcSEcCtD
Celecoxib—Nausea—Fluorouracil—skin cancer	3.16e-05	0.000409	CcSEcCtD
Celecoxib—Gastrointestinal pain—Docetaxel—skin cancer	3.14e-05	0.000406	CcSEcCtD
Celecoxib—Body temperature increased—Docetaxel—skin cancer	3.03e-05	0.000393	CcSEcCtD
Celecoxib—Abdominal pain—Docetaxel—skin cancer	3.03e-05	0.000393	CcSEcCtD
Celecoxib—Hypersensitivity—Docetaxel—skin cancer	2.83e-05	0.000366	CcSEcCtD
Celecoxib—Asthenia—Docetaxel—skin cancer	2.75e-05	0.000356	CcSEcCtD
Celecoxib—Pruritus—Docetaxel—skin cancer	2.72e-05	0.000351	CcSEcCtD
Celecoxib—MAPK14—Leptin signaling pathway—HRAS—skin cancer	2.71e-05	0.000824	CbGpPWpGaD
Celecoxib—PDPK1—Downstream signal transduction—IL6—skin cancer	2.71e-05	0.000824	CbGpPWpGaD
Celecoxib—PDPK1—Signaling by FGFR—IL6—skin cancer	2.7e-05	0.00082	CbGpPWpGaD
Celecoxib—PDPK1—Signaling by ERBB2—IL6—skin cancer	2.68e-05	0.000816	CbGpPWpGaD
Celecoxib—PDPK1—Signaling Pathways—GLI1—skin cancer	2.68e-05	0.000814	CbGpPWpGaD
Celecoxib—PDPK1—DAP12 signaling—IL6—skin cancer	2.67e-05	0.000812	CbGpPWpGaD
Celecoxib—MAPK14—Glucocorticoid receptor regulatory network—TP53—skin cancer	2.64e-05	0.000802	CbGpPWpGaD
Celecoxib—MAPK14—Signaling by VEGF—NRAS—skin cancer	2.63e-05	0.0008	CbGpPWpGaD
Celecoxib—MAPK14—NGF signalling via TRKA from the plasma membrane—BRAF—skin cancer	2.63e-05	0.000799	CbGpPWpGaD
Celecoxib—Diarrhoea—Docetaxel—skin cancer	2.63e-05	0.00034	CcSEcCtD
Celecoxib—PDPK1—Fc epsilon receptor (FCERI) signaling—HRAS—skin cancer	2.62e-05	0.000798	CbGpPWpGaD
Celecoxib—PDPK1—Signaling by FGFR in disease—HRAS—skin cancer	2.62e-05	0.000798	CbGpPWpGaD
Celecoxib—PDPK1—DAP12 interactions—HRAS—skin cancer	2.62e-05	0.000798	CbGpPWpGaD
Celecoxib—PDPK1—Signaling by EGFR—HRAS—skin cancer	2.6e-05	0.000791	CbGpPWpGaD
Celecoxib—MAPK14—TRAF6 Mediated Induction of proinflammatory cytokines—IL6—skin cancer	2.59e-05	0.000789	CbGpPWpGaD
Celecoxib—PDPK1—Signaling by EGFR in Cancer—HRAS—skin cancer	2.58e-05	0.000784	CbGpPWpGaD
Celecoxib—PDPK1—Signaling by PDGF—HRAS—skin cancer	2.57e-05	0.00078	CbGpPWpGaD
Celecoxib—PTGS2—Aryl Hydrocarbon Receptor—HRAS—skin cancer	2.56e-05	0.000778	CbGpPWpGaD
Celecoxib—ALB—Metabolism of lipids and lipoproteins—PLIN2—skin cancer	2.55e-05	0.000775	CbGpPWpGaD
Celecoxib—PDPK1—Signaling Pathways—SUFU—skin cancer	2.54e-05	0.000772	CbGpPWpGaD
Celecoxib—Dizziness—Docetaxel—skin cancer	2.54e-05	0.000329	CcSEcCtD
Celecoxib—PDPK1—Signaling by FGFR in disease—IL6—skin cancer	2.51e-05	0.000764	CbGpPWpGaD
Celecoxib—PDPK1—DAP12 interactions—IL6—skin cancer	2.51e-05	0.000764	CbGpPWpGaD
Celecoxib—PDPK1—Fc epsilon receptor (FCERI) signaling—IL6—skin cancer	2.51e-05	0.000764	CbGpPWpGaD
Celecoxib—PDPK1—Signaling by EGFR—IL6—skin cancer	2.49e-05	0.000757	CbGpPWpGaD
Celecoxib—PDPK1—Focal Adhesion—HRAS—skin cancer	2.48e-05	0.000754	CbGpPWpGaD
Celecoxib—CA4—Metabolism—ENO2—skin cancer	2.47e-05	0.00075	CbGpPWpGaD
Celecoxib—PDPK1—Signaling by EGFR in Cancer—IL6—skin cancer	2.47e-05	0.00075	CbGpPWpGaD
Celecoxib—MAPK14—Immune System—TLR7—skin cancer	2.46e-05	0.000749	CbGpPWpGaD
Celecoxib—MAPK14—Cellular Senescence—CDKN2A—skin cancer	2.46e-05	0.000749	CbGpPWpGaD
Celecoxib—PDPK1—Signaling by PDGF—IL6—skin cancer	2.46e-05	0.000747	CbGpPWpGaD
Celecoxib—PDPK1—Signaling by NGF—NRAS—skin cancer	2.44e-05	0.000743	CbGpPWpGaD
Celecoxib—PDPK1—Immune System—FOXO4—skin cancer	2.44e-05	0.000742	CbGpPWpGaD
Celecoxib—Vomiting—Docetaxel—skin cancer	2.44e-05	0.000316	CcSEcCtD
Celecoxib—MAPK14—Cellular responses to stress—CDK4—skin cancer	2.43e-05	0.00074	CbGpPWpGaD
Celecoxib—PDPK1—B Cell Activation—HRAS—skin cancer	2.43e-05	0.000738	CbGpPWpGaD
Celecoxib—Rash—Docetaxel—skin cancer	2.42e-05	0.000313	CcSEcCtD
Celecoxib—Dermatitis—Docetaxel—skin cancer	2.42e-05	0.000313	CcSEcCtD
Celecoxib—MAPK14—Glucocorticoid receptor regulatory network—IL6—skin cancer	2.42e-05	0.000734	CbGpPWpGaD
Celecoxib—Headache—Docetaxel—skin cancer	2.41e-05	0.000311	CcSEcCtD
Celecoxib—MAPK14—VEGFA-VEGFR2 Pathway—KRAS—skin cancer	2.4e-05	0.00073	CbGpPWpGaD
Celecoxib—PDPK1—Transmission across Chemical Synapses—HRAS—skin cancer	2.38e-05	0.000723	CbGpPWpGaD
Celecoxib—CA2—Metabolism—ENO2—skin cancer	2.37e-05	0.00072	CbGpPWpGaD
Celecoxib—MAPK14—MyD88 cascade initiated on plasma membrane—IL6—skin cancer	2.35e-05	0.000714	CbGpPWpGaD
Celecoxib—MAPK14—TCR Signaling Pathway—HRAS—skin cancer	2.34e-05	0.000712	CbGpPWpGaD
Celecoxib—MAPK14—TRAF6 mediated induction of NFkB and MAP kinases upon TLR7/8 or 9 activation—IL6—skin cancer	2.33e-05	0.000707	CbGpPWpGaD
Celecoxib—PDPK1—NGF signalling via TRKA from the plasma membrane—HRAS—skin cancer	2.32e-05	0.000707	CbGpPWpGaD
Celecoxib—ALB—Transmembrane transport of small molecules—SLC12A2—skin cancer	2.3e-05	0.000699	CbGpPWpGaD
Celecoxib—MAPK14—MyD88 dependent cascade initiated on endosome—IL6—skin cancer	2.28e-05	0.000694	CbGpPWpGaD
Celecoxib—Nausea—Docetaxel—skin cancer	2.28e-05	0.000295	CcSEcCtD
Celecoxib—MAPK14—Signaling by VEGF—KRAS—skin cancer	2.27e-05	0.000689	CbGpPWpGaD
Celecoxib—PDPK1—Disease—FOXO4—skin cancer	2.25e-05	0.000685	CbGpPWpGaD
Celecoxib—MAPK14—Integrated Pancreatic Cancer Pathway—PTGS2—skin cancer	2.25e-05	0.000685	CbGpPWpGaD
Celecoxib—MAPK14—TCR Signaling Pathway—IL6—skin cancer	2.24e-05	0.000682	CbGpPWpGaD
Celecoxib—PDPK1—NGF signalling via TRKA from the plasma membrane—IL6—skin cancer	2.22e-05	0.000676	CbGpPWpGaD
Celecoxib—MAPK14—B Cell Receptor Signaling Pathway—HRAS—skin cancer	2.21e-05	0.000671	CbGpPWpGaD
Celecoxib—MAPK14—Toll Like Receptor 9 (TLR9) Cascade—IL6—skin cancer	2.2e-05	0.00067	CbGpPWpGaD
Celecoxib—MAPK14—Innate Immune System—FOXO4—skin cancer	2.18e-05	0.000662	CbGpPWpGaD
Celecoxib—ALB—Selenium Micronutrient Network—PTGS2—skin cancer	2.17e-05	0.000658	CbGpPWpGaD
Celecoxib—MAPK14—MyD88:Mal cascade initiated on plasma membrane—IL6—skin cancer	2.17e-05	0.000658	CbGpPWpGaD
Celecoxib—MAPK14—Senescence and Autophagy in Cancer—TP53—skin cancer	2.17e-05	0.000658	CbGpPWpGaD
Celecoxib—PTGS2—C-MYB transcription factor network—NRAS—skin cancer	2.16e-05	0.000657	CbGpPWpGaD
Celecoxib—CA14—Metabolism—ERCC2—skin cancer	2.13e-05	0.000649	CbGpPWpGaD
Celecoxib—PDPK1—Signaling by NGF—KRAS—skin cancer	2.1e-05	0.000639	CbGpPWpGaD
Celecoxib—CYP2C9—Metabolism of lipids and lipoproteins—PLIN2—skin cancer	2.09e-05	0.000634	CbGpPWpGaD
Celecoxib—CA6—Metabolism—ERCC2—skin cancer	2.08e-05	0.000632	CbGpPWpGaD
Celecoxib—CA5A—Metabolism—ERCC2—skin cancer	2.08e-05	0.000632	CbGpPWpGaD
Celecoxib—MAPK14—MyD88-independent cascade—IL6—skin cancer	2.08e-05	0.000632	CbGpPWpGaD
Celecoxib—MAPK14—Senescence and Autophagy in Cancer—HRAS—skin cancer	2.07e-05	0.00063	CbGpPWpGaD
Celecoxib—MAPK14—VEGFA-VEGFR2 Pathway—HRAS—skin cancer	2.04e-05	0.00062	CbGpPWpGaD
Celecoxib—MAPK14—Toll-like Receptor Signaling Pathway—IL6—skin cancer	2.03e-05	0.000617	CbGpPWpGaD
Celecoxib—MAPK14—Signaling by NGF—BRAF—skin cancer	2.02e-05	0.000614	CbGpPWpGaD
Celecoxib—PTGS2—Integrated Pancreatic Cancer Pathway—CDK4—skin cancer	2.01e-05	0.000613	CbGpPWpGaD
Celecoxib—CA9—Metabolism—ENO2—skin cancer	1.99e-05	0.000606	CbGpPWpGaD
Celecoxib—MAPK14—Senescence and Autophagy in Cancer—IL6—skin cancer	1.98e-05	0.000603	CbGpPWpGaD
Celecoxib—MAPK14—Oxidative Stress Induced Senescence—TP53—skin cancer	1.96e-05	0.000596	CbGpPWpGaD
Celecoxib—MAPK14—Signaling Pathways—PTCH2—skin cancer	1.95e-05	0.000594	CbGpPWpGaD
Celecoxib—MAPK14—VEGFA-VEGFR2 Pathway—IL6—skin cancer	1.95e-05	0.000594	CbGpPWpGaD
Celecoxib—MAPK14—MAPK Signaling Pathway—NRAS—skin cancer	1.94e-05	0.000591	CbGpPWpGaD
Celecoxib—CA5B—Metabolism—ERCC2—skin cancer	1.94e-05	0.00059	CbGpPWpGaD
Celecoxib—PDPK1—Signaling Pathways—SHH—skin cancer	1.94e-05	0.000589	CbGpPWpGaD
Celecoxib—MAPK14—Signaling by VEGF—HRAS—skin cancer	1.93e-05	0.000585	CbGpPWpGaD
Celecoxib—PDPK1—Signaling Pathways—RASA1—skin cancer	1.92e-05	0.000585	CbGpPWpGaD
Celecoxib—MAPK14—Activated TLR4 signalling—IL6—skin cancer	1.87e-05	0.000568	CbGpPWpGaD
Celecoxib—MAPK14—Cellular responses to stress—CDKN2A—skin cancer	1.86e-05	0.000566	CbGpPWpGaD
Celecoxib—PTGS2—C-MYB transcription factor network—KRAS—skin cancer	1.86e-05	0.000566	CbGpPWpGaD
Celecoxib—MAPK14—Signaling by VEGF—IL6—skin cancer	1.84e-05	0.00056	CbGpPWpGaD
Celecoxib—PDPK1—Signaling Pathways—PTCH1—skin cancer	1.84e-05	0.000558	CbGpPWpGaD
Celecoxib—PDPK1—Signaling Pathways—SMO—skin cancer	1.84e-05	0.000558	CbGpPWpGaD
Celecoxib—ALB—Vitamin B12 Metabolism—IL6—skin cancer	1.83e-05	0.000555	CbGpPWpGaD
Celecoxib—PDPK1—Neuronal System—HRAS—skin cancer	1.82e-05	0.000554	CbGpPWpGaD
Celecoxib—MAPK14—TGF-beta Signaling Pathway—TP53—skin cancer	1.8e-05	0.000548	CbGpPWpGaD
Celecoxib—CA12—Metabolism—ERCC2—skin cancer	1.8e-05	0.000547	CbGpPWpGaD
Celecoxib—PDPK1—Signaling by NGF—HRAS—skin cancer	1.79e-05	0.000543	CbGpPWpGaD
Celecoxib—PDPK1—Signaling Pathways—PTGER4—skin cancer	1.79e-05	0.000543	CbGpPWpGaD
Celecoxib—MAPK14—Toll Like Receptor 4 (TLR4) Cascade—IL6—skin cancer	1.76e-05	0.000534	CbGpPWpGaD
Celecoxib—MAPK14—EGF/EGFR Signaling Pathway—KRAS—skin cancer	1.72e-05	0.000524	CbGpPWpGaD
Celecoxib—CA9—Cellular responses to stress—TP53—skin cancer	1.72e-05	0.000522	CbGpPWpGaD
Celecoxib—PDPK1—Signaling by NGF—IL6—skin cancer	1.71e-05	0.00052	CbGpPWpGaD
Celecoxib—MAPK14—MAPK Signaling Pathway—KRAS—skin cancer	1.67e-05	0.000509	CbGpPWpGaD
Celecoxib—MAPK14—NGF signalling via TRKA from the plasma membrane—NRAS—skin cancer	1.65e-05	0.000502	CbGpPWpGaD
Celecoxib—ALB—Folate Metabolism—TP53—skin cancer	1.62e-05	0.000493	CbGpPWpGaD
Celecoxib—MAPK14—BDNF signaling pathway—HRAS—skin cancer	1.61e-05	0.000489	CbGpPWpGaD
Celecoxib—PDPK1—Disease—ERCC2—skin cancer	1.61e-05	0.000488	CbGpPWpGaD
Celecoxib—MAPK14—Regulation of toll-like receptor signaling pathway—IL6—skin cancer	1.58e-05	0.000481	CbGpPWpGaD
Celecoxib—PTGS2—C-MYB transcription factor network—HRAS—skin cancer	1.58e-05	0.000481	CbGpPWpGaD
Celecoxib—PDPK1—Signaling Pathways—FOXO4—skin cancer	1.58e-05	0.00048	CbGpPWpGaD
Celecoxib—CA9—Cellular responses to stress—IL6—skin cancer	1.57e-05	0.000478	CbGpPWpGaD
Celecoxib—MAPK14—Toll-Like Receptors Cascades—IL6—skin cancer	1.57e-05	0.000476	CbGpPWpGaD
Celecoxib—PDPK1—Hemostasis—NRAS—skin cancer	1.55e-05	0.000471	CbGpPWpGaD
Celecoxib—MAPK14—Integrated Pancreatic Cancer Pathway—KRAS—skin cancer	1.51e-05	0.000459	CbGpPWpGaD
Celecoxib—PDPK1—Disease—TERT—skin cancer	1.51e-05	0.000458	CbGpPWpGaD
Celecoxib—MAPK14—MAPK Signaling Pathway—TP53—skin cancer	1.49e-05	0.000452	CbGpPWpGaD
Celecoxib—ALB—Folate Metabolism—IL6—skin cancer	1.49e-05	0.000452	CbGpPWpGaD
Celecoxib—MAPK14—Signaling Pathways—GLI2—skin cancer	1.48e-05	0.00045	CbGpPWpGaD
Celecoxib—MAPK14—Insulin Signaling—HRAS—skin cancer	1.48e-05	0.000449	CbGpPWpGaD
Celecoxib—MAPK14—Developmental Biology—CDK4—skin cancer	1.47e-05	0.000448	CbGpPWpGaD
Celecoxib—MAPK14—EGF/EGFR Signaling Pathway—HRAS—skin cancer	1.46e-05	0.000445	CbGpPWpGaD
Celecoxib—PTGS2—Selenium Micronutrient Network—IL6—skin cancer	1.46e-05	0.000443	CbGpPWpGaD
Celecoxib—CA4—Metabolism—ERCC2—skin cancer	1.43e-05	0.000436	CbGpPWpGaD
Celecoxib—MAPK14—NGF signalling via TRKA from the plasma membrane—KRAS—skin cancer	1.42e-05	0.000432	CbGpPWpGaD
Celecoxib—MAPK14—Signaling Pathways—MC1R—skin cancer	1.41e-05	0.000429	CbGpPWpGaD
Celecoxib—PTGS2—Metabolism—PLIN2—skin cancer	1.4e-05	0.000427	CbGpPWpGaD
Celecoxib—PDPK1—Innate Immune System—NRAS—skin cancer	1.39e-05	0.000424	CbGpPWpGaD
Celecoxib—MAPK14—Signaling Pathways—GLI1—skin cancer	1.39e-05	0.000423	CbGpPWpGaD
Celecoxib—CA2—Metabolism—ERCC2—skin cancer	1.37e-05	0.000418	CbGpPWpGaD
Celecoxib—MAPK14—Cellular Senescence—TP53—skin cancer	1.37e-05	0.000417	CbGpPWpGaD
Celecoxib—PTGS2—Disease—CSPG4—skin cancer	1.35e-05	0.000411	CbGpPWpGaD
Celecoxib—MAPK14—Integrated Pancreatic Cancer Pathway—TP53—skin cancer	1.34e-05	0.000408	CbGpPWpGaD
Celecoxib—PDPK1—Adaptive Immune System—NRAS—skin cancer	1.34e-05	0.000407	CbGpPWpGaD
Celecoxib—PDPK1—Hemostasis—KRAS—skin cancer	1.33e-05	0.000405	CbGpPWpGaD
Celecoxib—MAPK14—Signaling Pathways—SUFU—skin cancer	1.32e-05	0.000401	CbGpPWpGaD
Celecoxib—CA14—Metabolism—PTGS2—skin cancer	1.28e-05	0.000389	CbGpPWpGaD
Celecoxib—MAPK14—Signaling by NGF—NRAS—skin cancer	1.27e-05	0.000386	CbGpPWpGaD
Celecoxib—MAPK14—Immune System—FOXO4—skin cancer	1.27e-05	0.000386	CbGpPWpGaD
Celecoxib—PTGS2—Spinal Cord Injury—TP53—skin cancer	1.26e-05	0.000383	CbGpPWpGaD
Celecoxib—MAPK14—Cellular Senescence—IL6—skin cancer	1.25e-05	0.000381	CbGpPWpGaD
Celecoxib—CA5A—Metabolism—PTGS2—skin cancer	1.25e-05	0.000379	CbGpPWpGaD
Celecoxib—CA6—Metabolism—PTGS2—skin cancer	1.25e-05	0.000379	CbGpPWpGaD
Celecoxib—MAPK14—NGF signalling via TRKA from the plasma membrane—HRAS—skin cancer	1.21e-05	0.000367	CbGpPWpGaD
Celecoxib—PDPK1—Innate Immune System—KRAS—skin cancer	1.2e-05	0.000365	CbGpPWpGaD
Celecoxib—PDPK1—Disease—BRAF—skin cancer	1.19e-05	0.000363	CbGpPWpGaD
Celecoxib—PDPK1—Hemostasis—TP53—skin cancer	1.18e-05	0.00036	CbGpPWpGaD
Celecoxib—ALB—Selenium Micronutrient Network—IL6—skin cancer	1.18e-05	0.000359	CbGpPWpGaD
Celecoxib—CA5B—Metabolism—PTGS2—skin cancer	1.16e-05	0.000354	CbGpPWpGaD
Celecoxib—CA9—Metabolism—ERCC2—skin cancer	1.16e-05	0.000352	CbGpPWpGaD
Celecoxib—MAPK14—NGF signalling via TRKA from the plasma membrane—IL6—skin cancer	1.16e-05	0.000351	CbGpPWpGaD
Celecoxib—PTGS2—Spinal Cord Injury—IL6—skin cancer	1.15e-05	0.000351	CbGpPWpGaD
Celecoxib—PDPK1—Adaptive Immune System—KRAS—skin cancer	1.15e-05	0.00035	CbGpPWpGaD
Celecoxib—ALB—Metabolism—PLIN2—skin cancer	1.14e-05	0.000345	CbGpPWpGaD
Celecoxib—PDPK1—Hemostasis—HRAS—skin cancer	1.13e-05	0.000344	CbGpPWpGaD
Celecoxib—PTGS2—Metabolism—CSPG4—skin cancer	1.13e-05	0.000344	CbGpPWpGaD
Celecoxib—MAPK14—Signaling by NGF—KRAS—skin cancer	1.09e-05	0.000332	CbGpPWpGaD
Celecoxib—CA12—Metabolism—PTGS2—skin cancer	1.08e-05	0.000328	CbGpPWpGaD
Celecoxib—PDPK1—Signaling Pathways—TERT—skin cancer	1.05e-05	0.000321	CbGpPWpGaD
Celecoxib—MAPK14—Cellular responses to stress—TP53—skin cancer	1.04e-05	0.000315	CbGpPWpGaD
Celecoxib—PDPK1—Innate Immune System—HRAS—skin cancer	1.02e-05	0.00031	CbGpPWpGaD
Celecoxib—MAPK14—Signaling Pathways—SHH—skin cancer	1.01e-05	0.000306	CbGpPWpGaD
Celecoxib—MAPK14—Signaling Pathways—RASA1—skin cancer	1e-05	0.000304	CbGpPWpGaD
Celecoxib—PDPK1—Adaptive Immune System—HRAS—skin cancer	9.79e-06	0.000298	CbGpPWpGaD
Celecoxib—PDPK1—Innate Immune System—IL6—skin cancer	9.76e-06	0.000297	CbGpPWpGaD
Celecoxib—PTGS2—Integrated Pancreatic Cancer Pathway—KRAS—skin cancer	9.64e-06	0.000293	CbGpPWpGaD
Celecoxib—PDPK1—Disease—PTGS2—skin cancer	9.63e-06	0.000293	CbGpPWpGaD
Celecoxib—MAPK14—Signaling Pathways—SMO—skin cancer	9.54e-06	0.00029	CbGpPWpGaD
Celecoxib—MAPK14—Signaling Pathways—PTCH1—skin cancer	9.54e-06	0.00029	CbGpPWpGaD
Celecoxib—MAPK14—Cellular responses to stress—IL6—skin cancer	9.48e-06	0.000288	CbGpPWpGaD
Celecoxib—CYP2D6—Metabolism—PLIN2—skin cancer	9.37e-06	0.000285	CbGpPWpGaD
Celecoxib—CYP2C9—Metabolism—PLIN2—skin cancer	9.29e-06	0.000283	CbGpPWpGaD
Celecoxib—MAPK14—Signaling by NGF—HRAS—skin cancer	9.29e-06	0.000282	CbGpPWpGaD
Celecoxib—MAPK14—Signaling Pathways—PTGER4—skin cancer	9.29e-06	0.000282	CbGpPWpGaD
Celecoxib—ABCC4—Hemostasis—NRAS—skin cancer	9.19e-06	0.000279	CbGpPWpGaD
Celecoxib—PTGS2—Disease—SHH—skin cancer	9.18e-06	0.000279	CbGpPWpGaD
Celecoxib—PTGS2—Disease—ENO2—skin cancer	9.18e-06	0.000279	CbGpPWpGaD
Celecoxib—ALB—Metabolism—CSPG4—skin cancer	9.15e-06	0.000278	CbGpPWpGaD
Celecoxib—MAPK14—Gene Expression—ERCC2—skin cancer	8.99e-06	0.000273	CbGpPWpGaD
Celecoxib—MAPK14—Signaling by NGF—IL6—skin cancer	8.89e-06	0.00027	CbGpPWpGaD
Celecoxib—PDPK1—Signaling by GPCR—NRAS—skin cancer	8.88e-06	0.00027	CbGpPWpGaD
Celecoxib—CA4—Metabolism—PTGS2—skin cancer	8.6e-06	0.000261	CbGpPWpGaD
Celecoxib—PTGS2—Integrated Pancreatic Cancer Pathway—TP53—skin cancer	8.57e-06	0.000261	CbGpPWpGaD
Celecoxib—PDPK1—Signaling Pathways—BRAF—skin cancer	8.35e-06	0.000254	CbGpPWpGaD
Celecoxib—CA2—Metabolism—PTGS2—skin cancer	8.24e-06	0.000251	CbGpPWpGaD
Celecoxib—MAPK14—Signaling Pathways—FOXO4—skin cancer	8.2e-06	0.000249	CbGpPWpGaD
Celecoxib—MAPK14—Developmental Biology—NRAS—skin cancer	8.2e-06	0.000249	CbGpPWpGaD
Celecoxib—PDPK1—Immune System—NRAS—skin cancer	8.12e-06	0.000247	CbGpPWpGaD
Celecoxib—MAPK14—Hemostasis—NRAS—skin cancer	8.04e-06	0.000245	CbGpPWpGaD
Celecoxib—ABCC4—Hemostasis—KRAS—skin cancer	7.91e-06	0.00024	CbGpPWpGaD
Celecoxib—PTGS2—Metabolism—ENO2—skin cancer	7.69e-06	0.000234	CbGpPWpGaD
Celecoxib—PDPK1—Signaling by GPCR—KRAS—skin cancer	7.65e-06	0.000232	CbGpPWpGaD
Celecoxib—CYP2D6—Metabolism—CSPG4—skin cancer	7.56e-06	0.00023	CbGpPWpGaD
Celecoxib—PDPK1—Disease—NRAS—skin cancer	7.49e-06	0.000228	CbGpPWpGaD
Celecoxib—CYP2C9—Metabolism—CSPG4—skin cancer	7.49e-06	0.000228	CbGpPWpGaD
Celecoxib—PTGS2—Disease—FOXO4—skin cancer	7.48e-06	0.000228	CbGpPWpGaD
Celecoxib—MAPK14—Innate Immune System—NRAS—skin cancer	7.24e-06	0.00022	CbGpPWpGaD
Celecoxib—MAPK14—Developmental Biology—KRAS—skin cancer	7.06e-06	0.000215	CbGpPWpGaD
Celecoxib—ABCC4—Hemostasis—TP53—skin cancer	7.03e-06	0.000214	CbGpPWpGaD
Celecoxib—PDPK1—Immune System—KRAS—skin cancer	6.99e-06	0.000212	CbGpPWpGaD
Celecoxib—CA9—Metabolism—PTGS2—skin cancer	6.95e-06	0.000211	CbGpPWpGaD
Celecoxib—MAPK14—Hemostasis—KRAS—skin cancer	6.92e-06	0.00021	CbGpPWpGaD
Celecoxib—ABCC4—Hemostasis—HRAS—skin cancer	6.72e-06	0.000204	CbGpPWpGaD
Celecoxib—PDPK1—Signaling by GPCR—HRAS—skin cancer	6.5e-06	0.000198	CbGpPWpGaD
Celecoxib—PDPK1—Disease—KRAS—skin cancer	6.45e-06	0.000196	CbGpPWpGaD
Celecoxib—MAPK14—Innate Immune System—KRAS—skin cancer	6.23e-06	0.00019	CbGpPWpGaD
Celecoxib—ALB—Metabolism—ENO2—skin cancer	6.22e-06	0.000189	CbGpPWpGaD
Celecoxib—PDPK1—Signaling by GPCR—IL6—skin cancer	6.22e-06	0.000189	CbGpPWpGaD
Celecoxib—MAPK14—Hemostasis—TP53—skin cancer	6.15e-06	0.000187	CbGpPWpGaD
Celecoxib—CYP3A4—Metabolism—PLIN2—skin cancer	6.13e-06	0.000186	CbGpPWpGaD
Celecoxib—MAPK14—Developmental Biology—HRAS—skin cancer	6e-06	0.000182	CbGpPWpGaD
Celecoxib—PDPK1—Immune System—HRAS—skin cancer	5.94e-06	0.000181	CbGpPWpGaD
Celecoxib—MAPK14—Hemostasis—HRAS—skin cancer	5.89e-06	0.000179	CbGpPWpGaD
Celecoxib—MAPK14—Developmental Biology—IL6—skin cancer	5.74e-06	0.000175	CbGpPWpGaD
Celecoxib—PDPK1—Immune System—IL6—skin cancer	5.68e-06	0.000173	CbGpPWpGaD
Celecoxib—PDPK1—Disease—HRAS—skin cancer	5.48e-06	0.000167	CbGpPWpGaD
Celecoxib—MAPK14—Signaling Pathways—TERT—skin cancer	5.48e-06	0.000167	CbGpPWpGaD
Celecoxib—PTGS2—Disease—ERCC2—skin cancer	5.33e-06	0.000162	CbGpPWpGaD
Celecoxib—MAPK14—Innate Immune System—HRAS—skin cancer	5.3e-06	0.000161	CbGpPWpGaD
Celecoxib—PDPK1—Signaling Pathways—NRAS—skin cancer	5.25e-06	0.00016	CbGpPWpGaD
Celecoxib—PDPK1—Disease—IL6—skin cancer	5.25e-06	0.00016	CbGpPWpGaD
Celecoxib—CYP2D6—Metabolism—ENO2—skin cancer	5.14e-06	0.000156	CbGpPWpGaD
Celecoxib—CYP2C9—Metabolism—ENO2—skin cancer	5.09e-06	0.000155	CbGpPWpGaD
Celecoxib—MAPK14—Innate Immune System—IL6—skin cancer	5.07e-06	0.000154	CbGpPWpGaD
Celecoxib—PTGS2—Disease—TERT—skin cancer	5e-06	0.000152	CbGpPWpGaD
Celecoxib—CYP3A4—Metabolism—CSPG4—skin cancer	4.94e-06	0.00015	CbGpPWpGaD
Celecoxib—ALB—Metabolism of lipids and lipoproteins—PTGS2—skin cancer	4.87e-06	0.000148	CbGpPWpGaD
Celecoxib—PDPK1—Signaling Pathways—KRAS—skin cancer	4.52e-06	0.000137	CbGpPWpGaD
Celecoxib—PTGS2—Metabolism—ERCC2—skin cancer	4.47e-06	0.000136	CbGpPWpGaD
Celecoxib—MAPK14—Signaling Pathways—BRAF—skin cancer	4.34e-06	0.000132	CbGpPWpGaD
Celecoxib—MAPK14—Immune System—NRAS—skin cancer	4.22e-06	0.000128	CbGpPWpGaD
Celecoxib—ALB—Hemostasis—NRAS—skin cancer	4.16e-06	0.000126	CbGpPWpGaD
Celecoxib—PDPK1—Signaling Pathways—TP53—skin cancer	4.01e-06	0.000122	CbGpPWpGaD
Celecoxib—CYP2C9—Metabolism of lipids and lipoproteins—PTGS2—skin cancer	3.98e-06	0.000121	CbGpPWpGaD
Celecoxib—PTGS2—Disease—BRAF—skin cancer	3.96e-06	0.00012	CbGpPWpGaD
Celecoxib—PDPK1—Signaling Pathways—HRAS—skin cancer	3.84e-06	0.000117	CbGpPWpGaD
Celecoxib—PDPK1—Signaling Pathways—IL6—skin cancer	3.67e-06	0.000112	CbGpPWpGaD
Celecoxib—MAPK14—Immune System—KRAS—skin cancer	3.63e-06	0.00011	CbGpPWpGaD
Celecoxib—ALB—Metabolism—ERCC2—skin cancer	3.61e-06	0.00011	CbGpPWpGaD
Celecoxib—ALB—Hemostasis—KRAS—skin cancer	3.58e-06	0.000109	CbGpPWpGaD
Celecoxib—CYP3A4—Metabolism—ENO2—skin cancer	3.36e-06	0.000102	CbGpPWpGaD
Celecoxib—ALB—Hemostasis—TP53—skin cancer	3.18e-06	9.67e-05	CbGpPWpGaD
Celecoxib—MAPK14—Immune System—HRAS—skin cancer	3.09e-06	9.38e-05	CbGpPWpGaD
Celecoxib—ALB—Hemostasis—HRAS—skin cancer	3.04e-06	9.25e-05	CbGpPWpGaD
Celecoxib—CYP2D6—Metabolism—ERCC2—skin cancer	2.98e-06	9.07e-05	CbGpPWpGaD
Celecoxib—CYP2C9—Metabolism—ERCC2—skin cancer	2.96e-06	8.99e-05	CbGpPWpGaD
Celecoxib—MAPK14—Immune System—IL6—skin cancer	2.95e-06	8.98e-05	CbGpPWpGaD
Celecoxib—MAPK14—Signaling Pathways—NRAS—skin cancer	2.73e-06	8.29e-05	CbGpPWpGaD
Celecoxib—PTGS2—Disease—NRAS—skin cancer	2.49e-06	7.56e-05	CbGpPWpGaD
Celecoxib—MAPK14—Signaling Pathways—KRAS—skin cancer	2.35e-06	7.14e-05	CbGpPWpGaD
Celecoxib—ALB—Metabolism—PTGS2—skin cancer	2.17e-06	6.59e-05	CbGpPWpGaD
Celecoxib—PTGS2—Disease—KRAS—skin cancer	2.14e-06	6.51e-05	CbGpPWpGaD
Celecoxib—MAPK14—Signaling Pathways—TP53—skin cancer	2.09e-06	6.34e-05	CbGpPWpGaD
Celecoxib—MAPK14—Signaling Pathways—HRAS—skin cancer	2e-06	6.07e-05	CbGpPWpGaD
Celecoxib—CYP3A4—Metabolism—ERCC2—skin cancer	1.95e-06	5.93e-05	CbGpPWpGaD
Celecoxib—MAPK14—Signaling Pathways—IL6—skin cancer	1.91e-06	5.81e-05	CbGpPWpGaD
Celecoxib—PTGS2—Disease—HRAS—skin cancer	1.82e-06	5.53e-05	CbGpPWpGaD
Celecoxib—CYP2D6—Metabolism—PTGS2—skin cancer	1.79e-06	5.44e-05	CbGpPWpGaD
Celecoxib—CYP2C9—Metabolism—PTGS2—skin cancer	1.77e-06	5.39e-05	CbGpPWpGaD
Celecoxib—PTGS2—Disease—IL6—skin cancer	1.74e-06	5.3e-05	CbGpPWpGaD
Celecoxib—CYP3A4—Metabolism—PTGS2—skin cancer	1.17e-06	3.56e-05	CbGpPWpGaD
